Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.

Journal for immunotherapy of cancer - 7 Jul 2026

Su Yu-Li, Huang Shih-Yu, Kuo Chung-Wen, Xiao Ling-Yi, Lin Chang-Ting, Chen Yi-Hua, Chang Li-Chung, Kuo Ming-Chun, Wu Chia-Che, Peng Jei-Ming, Wu Chia-Ling, Huang Hsuan-Ying, Chien Chih-Yen

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICIs) have significantly improved overall survival in metastatic urothelial carcinoma (mUC). However, predictive biomarkers for therapeutic response remain insufficiently defined. Although some genomic alterations have been implicated in modulating tumor immunogenicity and ICI sensitivity in other cancers, evidence in mUC remains limited and warrants further...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Class I Phosphatidylinositol 3-Kinases

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42413983
DOI: 10.1136/jitc-2026-014770
PMCID: PMC13343094

Genes

PIK3CA
NLRC5
ADAMTSL1
B2M
NSD1
PRKDC

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.PMID 42413983Read ↗

Immune Checkpoint Inhibitor Resistance in Genitourinary Cancers: Mechanisms, Biomarkers, and Emerging Therapeutic StrategiesSemantic proximity Read ↗

PIK3CA mutation-induced immune microenvironment remodeling sensitizes cervical cancer to immunotherapy.Semantic proximity Read ↗

Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.Semantic proximity Read ↗

Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.Semantic proximity Read ↗

The Central Role of Immune Checkpoint Receptors in Genitourinary Tumor Immunotherapy: Mechanisms, Biomarkers, and Therapeutic LandscapeSemantic proximity Read ↗

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.Semantic proximity Read ↗

Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer.Semantic proximity Read ↗

Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial CarcinomaSemantic proximity Read ↗

The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohortSemantic proximity Read ↗

Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.Semantic proximity Read ↗

Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.Semantic proximity Read ↗

DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.